Cited 20 times in
Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신성재 | - |
dc.date.accessioned | 2018-07-20T08:20:26Z | - |
dc.date.available | 2018-07-20T08:20:26Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1027-3719 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161104 | - |
dc.description.abstract | SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE: To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS: With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONCLUSION: Our results suggest that once-daily AMK for 4 weeks with a target Cmax of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | The Union | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Amikacin/administration & dosage* | - |
dc.subject.MESH | Amikacin/adverse effects | - |
dc.subject.MESH | Amikacin/pharmacokinetics | - |
dc.subject.MESH | Anti-Bacterial Agents/administration & dosage* | - |
dc.subject.MESH | Anti-Bacterial Agents/adverse effects | - |
dc.subject.MESH | Anti-Bacterial Agents/pharmacokinetics | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Monitoring/methods | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hearing Loss/chemically induced | - |
dc.subject.MESH | Hearing Loss/epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Diseases/chemically induced | - |
dc.subject.MESH | Kidney Diseases/epidemiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Mycobacterium Infections, Nontuberculous/drug therapy* | - |
dc.subject.MESH | Mycobacterium Infections, Nontuberculous/microbiology | - |
dc.subject.MESH | Mycobacterium abscessus/isolation & purification* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tinnitus/chemically induced | - |
dc.subject.MESH | Tinnitus/epidemiology | - |
dc.title | Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Microbiology | - |
dc.contributor.googleauthor | Lee, H. | - |
dc.contributor.googleauthor | Sohn, Y. M. | - |
dc.contributor.googleauthor | Ko, J. Y. | - |
dc.contributor.googleauthor | Lee, S-Y. | - |
dc.contributor.googleauthor | Jhun, B. W. | - |
dc.contributor.googleauthor | Park, H. Y. | - |
dc.contributor.googleauthor | Jeon, K. | - |
dc.contributor.googleauthor | Kim, D. H. | - |
dc.contributor.googleauthor | Kim, S-Y. | - |
dc.contributor.googleauthor | Choi, J. E. | - |
dc.contributor.googleauthor | Moon, I. J. | - |
dc.contributor.googleauthor | Shin, S. J. | - |
dc.contributor.googleauthor | Park, H. J. | - |
dc.contributor.googleauthor | Koh, W-J. | - |
dc.identifier.doi | 10.5588/ijtld.16.0791 | - |
dc.contributor.localId | A02114 | - |
dc.relation.journalcode | J01167 | - |
dc.identifier.eissn | 1815-7920 | - |
dc.identifier.pmid | 28633708 | - |
dc.identifier.url | http://www.ingentaconnect.com/contentone/iuatld/ijtld/2017/00000021/00000007/art00018 | - |
dc.contributor.alternativeName | Shin, Sung Jae | - |
dc.contributor.affiliatedAuthor | Shin, Sung Jae | - |
dc.citation.volume | 21 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 818 | - |
dc.citation.endPage | 824 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, Vol.21(7) : 818-824, 2017 | - |
dc.identifier.rimsid | 60993 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.